The rising prevalence of chronic diseases is one of the key factors expected to trigger the market growth during the forecast period. Chronic diseases including diabetes, stroke, cancer, arthritis, and others are responsible for seven out of 10 deaths among the people in the US. In addition, autoimmune diseases are a key health concern, further, driving the demand for CRP tests during the forecast period. The ability for diagnosing diseases increases significantly using CRP tests, while impacting the market growth positively during the forecast period. Analysts have predicted that the C-reactive protein test market will register a CAGR of over 1% by 2023.
Rising incidence of HIV in developing countries
The increasing incidence of HIV infections, especially in developing countries, posed a challenge to the economy. This has further necessitated the need for monitoring HIV disease activity through low-cost techniques such as CRP testing. HIV is a virus that enters the blood, and attacks and destroys the body’s immune system, which results in the development of AIDS. Importance of evaluating the CRP level in HIV affected patients through hs-CRP assays has increased the demand for CRP testing and is expected to increase further during the forecast period, boosting the market growth.
Increasing data integrity issues
CRP testing data relies on recording observation, in which error may occur, resulting in manipulation and wrong information of results. This reduces the reliability of tests, which hinders market growth.
For the detailed list of factors that will drive and challenge the growth of the C-reactive protein test market during 2019-2023, view our report.
The market appears to be moderately concentrated and with the presence of a few market players. Vendors are offering high-end innovative products that are using protein analysis to detect chronic diseases. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Our reports have been used by over 10K customers, including:
Contact Dermatitis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H2 2020, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape. Contact dermatitis is a type of skin inflammation...
Uveal Melanoma - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H2 2020, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape. Uveal melanoma, the most common intraocular tumor, is a disease...
The global microbial identification market size is estimated to be USD 3.2 billion in 2020 and projected to reach USD 5.7 billion by 2025, at a CAGR of 12.2%. Growth in this market is largely driven by the rising incidence of infectious diseases and the increasing frequency of pandemics, technological advancements, increasing food safety concerns,...
Hepatitis C (HCV) Pipeline Overview The Q4 Hepatitis C (HCV) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Hepatitis C (HCV), provides an update on the mechanism of action and targets, licensing and collaboration...
Influenza B Infections Pipeline Overview The Q4 Influenza B Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Influenza B Infections, provides an update on the mechanism of action and targets, licensing and...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.